Literature DB >> 2899828

High affinity binding of [125I-Tyr11]somatostatin-14 to human small cell lung carcinoma (NCI-H69).

J E Taylor1, D H Coy, J P Moreau.   

Abstract

The in vitro binding of [125I-Tyr11]somatostatin-14 (SRIF-14) to membranes prepared from cultured human small cell lung carcinoma (SCLC) cells (NCI-H69) has been characterized. Binding to SCLC was monophasic and of high affinity (Kd = 0.59 +/- 0.02 nM, n = 3). The estimated Bmax was 173 +/- 2.4 fmol/mg protein. Receptors were also present on solid NCI-H69 tumors grown in vivo in the athymic nude mouse. However, the concentration was only about 10% of that observed in cell culture. Biologically-active SRIF analogues were potent inhibitors of [125I-Tyr11]SRIF-14 binding, and an analysis of the pharmacological specificity indicated that the SCLC receptor was of the peripheral (e.g., non-neural) subtype. The presence of SRIF receptors on SCLC membranes may indicate that SRIF has a role in regulation of SCLC function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899828     DOI: 10.1016/0024-3205(88)90521-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.

Authors:  Jeremy Lewin; Carleen Cullinane; Tim Akhurst; Kelly Waldeck; D Neil Watkins; Aparna Rao; Peter Eu; Linda Mileshkin; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-16       Impact factor: 9.236

2.  Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma.

Authors:  C M Kirsch; J von Pawel; I Grau; K Tatsch
Journal:  Eur J Nucl Med       Date:  1994-12

3.  Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.

Authors:  K J O'Byrne; J T Ennis; P J Freyne; L J Clancy; J S Prichard; D N Carney
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

4.  Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer.

Authors:  V M Macaulay; I E Smith; M J Everard; J D Teale; J C Reubi; J L Millar
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.